Neurocrine Biosciences Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Okay. We will continue with the next session. Good morning, everyone. I'm Paul Choi, the SMid cap biotechnology analyst here at Goldman Sachs. I'm very pleased to host in our next session Neurocrine Biosciences. Joining us from management is Kevin Gorman, the CEO; and we are also pleased to have Eiry Roberts, the Chief Medical Officer, with us here as well from the West Coast. It's early there. So we certainly appreciate both of you joining us here for our morning session.
As with the prior sessions here at the Goldman Sachs conference, I'll kick it off with some introductory remarks, and then I'll turn it over to Kevin, after which we'll go into the Q&A session. If along the way, if any clients or investors have questions for Neurocrine, please feel free to submit them through the Goldman Sachs Research portal, and time permitting at the end, we'll read 1 or 2 questions and we'll let the company respond to them. Alternatively, you can e-mail the questions to me directly. And again, if we have a minute or 2 at the end,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |